CVS Health: The Surprising Healthcare Outlier

CVS Health Corporation has outperformed peers, overcoming industry headwinds through effective management and strategic execution. CVS delivered a Q1 beat-and-raise, expects margin expansion in 2026, and projects low double-digit investor returns. While Health Services and Insurance segments anticipate mid-single-digit growth, retail is set for gradual decline but with margin improvements. At $105, CVS trades at a premium to its historical average but remains discounted versus peers, justifying a reiterated 'Buy' rating.

CVS Health Corporation (CVS) isn't a name most investors associate with market-beating returns and industry leadership, but that's exactly what the company delivered under its new leadership. The health services industry has been dealing